New analysis for 2023 shows signs of post-pandemic recovery; breast cancer remains most studied disease area.
Phesi Releases Annual Analysis of Clinical Development for 2023
You May Also Like
Global Launch Strategies in the Current Political Climate
February 19, 2025
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
February 19, 2025
Navigating Distrust: Pharma in the Age of Social Media
February 18, 2025
+ There are no comments
Add yours